Omfiloctocog alfa clinical trials
Also written SCT800.
How each study uses omfiloctocog alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the omfiloctocog alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2019 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Sinocelltech Ltd. (5) · Institute of Hematology & Blood Diseases Hospital, China (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test omfiloctocog alfa.
- Dec 2026ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer InhibitorPhase 4 · Institute of Hematology & Blood Diseases Hospital, China
Studies
Open first, then newest update. How each study uses omfiloctocog alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer InhibitorRecruitingPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT05888870Written as SCT800 and Daratumumab
- Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.RecruitingPhase 4Sinocelltech Ltd.NCT03947567Written as Recombinant Human Coagulation FVIII
- Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia ACompletedPhase 3Sinocelltech Ltd.NCT03815318Written as Recombinant Human Coagulation FVIII
- Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.Status unknownPhase 3Sinocelltech Ltd.NCT03947320Written as Recombinant Human Coagulation FVIII
- Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia AStatus unknownPhase 3Sinocelltech Ltd.NCT02921945Written as SCT800
- Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia AStatus unknownPhase 1Sinocelltech Ltd.NCT02888223Written as SCT800
Codes
What other systems call omfiloctocog alfa · ClinicalTrials.gg INT015396
- UNII (FDA) 74D9ZOJ6IROMFILOCTOCOG ALFAOne source FDA
- NCI Thesaurus C175177Omfiloctocog AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 74D9ZOJ6IR | OMFILOCTOCOG ALFA | One source FDA |
| NCI Thesaurus | C175177 | Omfiloctocog Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.